Clinical Trials
20 trialsInterleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer
Providence Health & Services
High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer
University of Texas Southwestern Medical Center
Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
Loma Linda University
Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer
University of Wisconsin, Madison
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
National Institutes of Health Clinical Center (CC)
DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC
Dartmouth-Hitchcock Medical Center
Interleukin-2 in Metastatic Kidney Cancer
Western Regional Medical Center
Vaccine Treatment of Kidney Cancer
National Institutes of Health Clinical Center (CC)
Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer
Loyola University
Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer
The Methodist Hospital Research Institute
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
National Institutes of Health Clinical Center (CC)
MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
National Institutes of Health Clinical Center (CC)
Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer
Northwestern University
Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer
H. Lee Moffitt Cancer Center and Research Institute
Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer
Northwestern University
Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer
National Institutes of Health Clinical Center (CC)
Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2
H. Lee Moffitt Cancer Center and Research Institute
Granulocyte-macrophage Colony-stimulating Factor, Interferon and Interleukin-2 as Adjuvant Treatment for Renal Cancer
Kidney Cancer Research Bureau